180 related articles for article (PubMed ID: 34559824)
1. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
Suwabe T; Barrera FJ; Rodriguez-Gutierrez R; Ubara Y; Hogan MC
PLoS One; 2021; 16(9):e0257606. PubMed ID: 34559824
[TBL] [Abstract][Full Text] [Related]
2. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
3. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
Myint TM; Rangan GK; Webster AC
Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
5. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
6. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
7. Changes in Kidney and Liver Volumes in Patients With Autosomal Dominant Polycystic Kidney Disease Before and After Dialysis Initiation.
Suwabe T; Ubara Y; Oba Y; Mizuno H; Ikuma D; Yamanouchi M; Sekine A; Tanaka K; Hasegawa E; Hoshino J; Sawa N
Mayo Clin Proc Innov Qual Outcomes; 2023 Feb; 7(1):69-80. PubMed ID: 36712823
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
9. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
Higashihara E; Nutahara K; Okegawa T; Tanbo M; Mori H; Miyazaki I; Nitatori T; Kobayashi K
Clin Exp Nephrol; 2015 Aug; 19(4):746-52. PubMed ID: 25351823
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
11. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
12. Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.
van Gastel MDA; Edwards ME; Torres VE; Erickson BJ; Gansevoort RT; Kline TL
J Am Soc Nephrol; 2019 Aug; 30(8):1514-1522. PubMed ID: 31270136
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Tsukamoto S; Urate S; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Front Pharmacol; 2022; 13():885457. PubMed ID: 35662736
[No Abstract] [Full Text] [Related]
14. Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
Jo WR; Kim SH; Kim KW; Suh CH; Kim JK; Kim H; Lee JG; Oh WY; Choi SE; Pyo J
Eur J Radiol; 2017 Oct; 95():56-65. PubMed ID: 28987699
[TBL] [Abstract][Full Text] [Related]
15. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
16. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Hogan MC; Masyuk TV; Page L; Holmes DR; Li X; Bergstralh EJ; Irazabal MV; Kim B; King BF; Glockner JF; Larusso NF; Torres VE
Nephrol Dial Transplant; 2012 Sep; 27(9):3532-9. PubMed ID: 22773240
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
He Q; Lin C; Ji S; Chen J
Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
Liu YM; Shao YQ; He Q
Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
